# A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck

> **NCT02479178** · PHASE2 · TERMINATED · sponsor: **BIND Therapeutics** · enrollment: 73 (actual)

## Conditions studied

- Urothelial Carcinoma
- Cholangiocarcinoma
- Cervical Cancer
- Squamous Cell Carcinoma of Head and Neck

## Interventions

- **DRUG:** BIND-014 (docetaxel nanoparticles for injectable suspension)

## Key facts

- **NCT ID:** NCT02479178
- **Lead sponsor:** BIND Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06
- **Primary completion:** 2016-10
- **Final completion:** 2020-01
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2016-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02479178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02479178, "A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02479178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*